Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Hans‐Jochem Kolb, Andreas Neubauer et al.|Leukemia|2017Cited by 339
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsJan‐Niklas Eckardt, Jan Moritz Middeke, Friedrich Stölzel et al.|Journal of Hematology & Oncology|2022Cited by 58
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classificationJan‐Niklas Eckardt, Christoph Röllig, Marius Bill et al.|Leukemia|2023Cited by 36